Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
John has deep experience in intellectual property litigation and regularly litigates patent infringement cases. Since 2006 his practice has focused on pharmaceutical litigation, representing generic drug manufacturers in high-stakes patent litigation brought under the Hatch-Waxman Act. With a Ph.D. in chemistry, his depth of scientific knowledge and trial experience makes him uniquely qualified to advise his pharmaceutical clients and develop trial strategies for effective trial presentations or negotiating favorable settlements. He represents clients throughout all phases of litigation including both jury and bench trials before the federal district courts, the Court of Appeals for the Federal Circuit, the Supreme Court of the United States, and the United States International Trade Commission. He also has litigated patent, trademark, and trade secret cases involving varying technologies including medical devices, computer software, and food processing technology.
Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.
Law360, The Wall Street Journal, Thomson Reuters, Bloomberg Business, AmLaw Daily, Deal Pipeline, LSIPR, IP Pro Life Sciences
Shortly after approving the first biosimilar under the abbreviated approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the FDA has recently issued 3 final guidances regarding biosimilars. Biological products, or “biologics,” are pharmaceutical products created from biological sources. Unlike chemically synthesized pharmaceuticals, biologics are isolated from natural sources, and... Continue Reading